Singapore, Dec. 18 -- Japan-based PRISM BioLab and US-based startup Talus Bioscience, Inc. have entered into a collaboration to discover novel inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets.

By combining Talus Bio's assay technologies for screening TF and PPI inhibitors in native cellular environment with PRISM's chemistry designed to target protein-protein interactions, companies are in a unique position to discover and develop drugs against these challenging targets.

Published by HT Digital Content Services with permission from BioSpectrum Asia....